HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2018
At a glance
- Drugs DT2219ARL (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2018 Status changed from recruiting to completed.
- 05 Sep 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 05 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History